Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Matrix metalloproteinase-13 (MMP-13), also known as collagenase 3, is a zinc-dependent endopeptidase that degrades components of the extracellular matrix (ECM), particularly type II collagen. It plays a key role in cartilage and bone remodeling, and its overexpression is implicated in osteoarthritis, rheumatoid arthritis, and cancer invasion/metastasis, making it an attractive drug target.
Inhibition of MMP-13 enzymatic activity, preventing ECM degradation
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Matrix metalloproteinase-13 (MMP-13).